Innocare
A Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$407m Valuation: $2.9b | Private Placement VC | ||
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 76369 % | (40 %) | 18 % | 37 % | 44 % | 27 % | 36 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 1 % | (132 %) | (68 %) | (31 %) | (22 %) | (12 %) | 4 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (6 %) | (142 %) | (85 %) | (44 %) | (23 %) | (14 %) | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 69 % | 102 % | 102 % | 81 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
InnoCare Pharma is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The company operates in the highly specialized field of oncology and immunology, focusing on innovative therapies that address unmet medical needs. InnoCare serves a global market, with a particular emphasis on the U.S. and China, where it conducts extensive clinical trials and research activities.
The company's business model is built around a fully integrated biopharmaceutical platform that encompasses all stages of the drug development cycle. This includes drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing, quality control, and commercialization. By maintaining all these functions in-house, InnoCare enhances operational efficiency and ensures high-quality standards throughout the development process.
InnoCare generates revenue through the commercialization of its proprietary drug candidates, licensing agreements, and partnerships with other pharmaceutical companies. The company has a strong pipeline of drug candidates, including ICP-192, a highly selective pan FGFR inhibitor targeting multiple solid tumors with FGFR gene aberrations, which has received approval from the U.S. FDA for clinical investigations.
Keywords: biopharmaceutical, oncology, immunology, cancer treatment, autoimmune diseases, drug development, clinical trials, FGFR inhibitor, R&D platform, commercialization.